Nipah Virus Vaccine: Japan's Clinical Trial Begins Against a Disease With Up to 75% Fatality Rate
A Japanese-developed measles-vector vaccine against Nipah virus, a disease with up to 75% fatality, began Phase I clinical trials in Belgium in June 2026. Learn about the approach and Japan's role in global pandemic preparedness.